SBFM vs. MYNZ, SNSE, TXMD, FLGC, PMCB, CHRO, TLPH, KPRX, KLTO, and JAGX
Should you be buying Sunshine Biopharma stock or one of its competitors? The main competitors of Sunshine Biopharma include Mainz Biomed (MYNZ), Sensei Biotherapeutics (SNSE), TherapeuticsMD (TXMD), Flora Growth (FLGC), PharmaCyte Biotech (PMCB), Chromocell Therapeutics (CHRO), Talphera (TLPH), Kiora Pharmaceuticals (KPRX), Klotho Neurosciences (KLTO), and Jaguar Health (JAGX). These companies are all part of the "pharmaceutical products" industry.
Sunshine Biopharma vs.
Mainz Biomed (NASDAQ:MYNZ) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability, community ranking and earnings.
Mainz Biomed currently has a consensus price target of $67.00, suggesting a potential upside of 1,067.25%. Sunshine Biopharma has a consensus price target of $15.00, suggesting a potential upside of 512.24%. Given Mainz Biomed's higher possible upside, analysts plainly believe Mainz Biomed is more favorable than Sunshine Biopharma.
Mainz Biomed has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.
In the previous week, Mainz Biomed had 5 more articles in the media than Sunshine Biopharma. MarketBeat recorded 5 mentions for Mainz Biomed and 0 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 0.00 beat Mainz Biomed's score of -0.20 indicating that Sunshine Biopharma is being referred to more favorably in the news media.
Mainz Biomed has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -12.82%. Mainz Biomed's return on equity of 0.00% beat Sunshine Biopharma's return on equity.
42.0% of Sunshine Biopharma shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 0.1% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Mainz Biomed received 12 more outperform votes than Sunshine Biopharma when rated by MarketBeat users. However, 100.00% of users gave Sunshine Biopharma an outperform vote while only 73.68% of users gave Mainz Biomed an outperform vote.
Sunshine Biopharma has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Mainz Biomed beats Sunshine Biopharma on 9 of the 17 factors compared between the two stocks.
Get Sunshine Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBFM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sunshine Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:SBFM) was last updated on 2/22/2025 by MarketBeat.com Staff
Free SBFM Stock Alerts